ScripIt is early days but Incyte has caught the eye of analysts with promising first data from two studies of its first-in-class monoclonal antibody for patients with mutant calreticulin (mutCALR)-expressi
Pink SheetThe US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti
ScripMerck & Co.’s initial Phase II/III waveLINE-003 data for zilovertamab vedotin (zilo-V) in diffuse large B-cell lymphoma (DLBCL) at the American Society of Clinical Oncology meeting in Chicago rais
ScripSun signaled launch action ahead in the US and a change in plan for certain pipeline specialty assets, even as it awaits, like other industry peers , more clarity on details around US President Don